CMTS0929 for Clostridioides Difficile Infection

Launched by THE SECOND HOSPITAL OF NANJING MEDICAL UNIVERSITY · Feb 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CMTS0929 for patients suffering from Clostridioides difficile infection (CDI), which is a serious type of gut infection. The goal of this study is to see how safe and effective this treatment is for people who have CDI. The trial is currently not recruiting participants but will include adults aged 18 to 75, regardless of gender. To be eligible, participants must have a confirmed CDI diagnosis and be experiencing symptoms like diarrhea.

If you or a loved one qualifies for this trial, you can expect to receive the CMTS0929 treatment and will be monitored closely by researchers to ensure safety and effectiveness. It’s important to note that certain health conditions, recent surgeries, or other infections may prevent someone from participating. Participants will also need to provide informed consent, meaning they understand the study and agree to take part. This study aims to help find better treatments for CDI, which could improve the health of many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Subjects must meet all of the following inclusion criteria to enter the study:
• • 1. At the time of informed consent, the age is between 18 and 75 years old (inclusive), including both males and non - pregnant, non - lactating females.
• • 2. At the time of screening, meet the diagnostic criteria for Clostridioides difficile infection: a)There is a medical record proving a confirmed CDI before screening (laboratory tests show positive results for Clostridioides difficile or its toxins): positive results in Clostridioides difficile toxin detection (determined by EIAs) or colonoscopy indicating pseudomembranous colitis; or positive GDH with negative toxin results, along with obvious predisposing factors and diarrhea. b)Have an episode of CDI - related diarrhea, that is, having at least 3 bowel movements per day for at least two consecutive days and the stools are unformed (Bristol Stool Form Scale score of 6 - 7).
• • 3. The subject or their legal representative provides informed consent, fully understands the purpose of the study, can communicate well with the researcher, and can understand and comply with all the requirements of this study.
• Exclusion Criteria:
• Subjects meeting any of the following exclusion criteria must be excluded from the study:
• • 1. Subjects with immunodeficiency (such as HIV infection, or absolute neutrophil count \< 0.5×10⁹/L, or total lymphocyte count \< 0.5×10⁹/L, etc.), or those using immunosuppressants, or those using medium - to high - dose steroid hormones (≥20 g/d prednisone or equivalent steroid hormones).
• • 2. Subjects with rectal outlet obstruction (such as rectal mucosal prolapse) or significant intestinal stenosis that, as evaluated by the researcher, cannot undergo cTET.
• • 3. Before screening, subjects are diagnosed or clinically suspected of having an infection with other pathogenic microorganisms in addition to Clostridioides difficile.
• • 4. Within 6 months before screening, subjects have undergone major abdominal surgery (excluding laparoscopic cholecystectomy or appendectomy), or have previously undergone partial or total colectomy, or partial small intestine resection, or gastroduodenal surgery.
• • 5. At the time of screening, the subject or legal representative refuses to use effective contraceptive measures within 3 months after the last treatment.
• • 6. As judged by the researcher, the subject is not suitable to participate in this clinical study, or participation in this clinical study cannot guarantee the rights and interests of the subject.